Physician profile
Ernest Ast
NPI 1982779757
$10,310.75
in general payments reported to CMS, 2019-2025
9 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2022: $30.00 · 2023: $9,579 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,470 · Food and Beverage: $233 · Education: $99.00 · Travel and Lodging: $89.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,470.00 |
| Food and Beverage | $233.12 |
| Education | $99.00 |
| Travel and Lodging | $89.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $7,759.45 | 2023 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $1,819.65 | 2023 | Sotyktu |
| Pfizer INC. | $283.49 | 2019-2025 | |
| Galderma Laboratories, L.P. | $226.22 | 2019 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Leo Pharma INC. | $46.72 | 2025 | Anzupgo |
| Amgen INC. | $46.22 | 2019 | |
| Epi Health, LLC | $30.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Ast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.